Rare Disease MSL Team Excellence: Benchmarking Key Performance Indicators

KEY TOPICS

• Field Challenges
• KOL Access - Post Pandemic
• Customer Engagement Preference
• Proactive Outreach
• F2F Meetings: Value and Ideal Mix

• How would you rate the post-pandemic ability of rare disease MSLs to interact with KOLs and HCPs?
• What do KOLs and HCPs served by rare disease MSL teams prefer in terms of engagement and support?
• Approximately how many KOLs are currently supported by an individual MSL of each type at rare disease organizations?
• Approximately how many F2F and virtual meetings are asked of each MSL within the rare disease organization?
• Percentage of proactive interactions in rare disease segment
• MSL proactivity index in rare disease segment
• Are F2F interactions assigned a higher value on the rare disease MSL scorecard?
• How many F2F meetings are targeted monthly?

• Ease of access: Some 62% of Rare Disease teams report that gaining access to KOLs and physicians in-person has grown more difficult over the past 6 months. Meanwhile, 62% of companies indicate accessing KOLs virtually “has been relatively easy.”

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.